• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

再生障碍性贫血的发病率:诊断标准的相关性。国际粒细胞缺乏症和再生障碍性贫血研究组

Incidence of aplastic anemia: the relevance of diagnostic criteria. By the International Agranulocytosis and Aplastic Anemia Study.

出版信息

Blood. 1987 Dec;70(6):1718-21.

PMID:3676511
Abstract

The incidence of aplastic anemia was estimated in a 4-year study conducted in Israel and seven areas in Europe. Strict definition criteria were used, and all data and bone marrow specimens were reviewed by a panel of experienced hematologists. Complete ascertainment of cases was attempted by establishing a telephone network including all relevant hospitals in the study areas. The incidence of aplastic anemia was estimated to be less than three per million per year, a figure lower than previously reported. The most likely explanation for the differences among studies is variation in diagnostic criteria, which might lead to an overestimation of the incidence in some previous studies.

摘要

在以色列和欧洲七个地区进行的一项为期4年的研究中,对再生障碍性贫血的发病率进行了估算。研究采用了严格的定义标准,所有数据和骨髓标本均由一组经验丰富的血液学家进行审查。通过建立一个包括研究区域内所有相关医院的电话网络,试图实现病例的完全确诊。再生障碍性贫血的发病率估计低于每年百万分之三,这一数字低于先前报告的数字。不同研究结果存在差异的最可能原因是诊断标准的不同,这可能导致一些先前研究中发病率的高估。

相似文献

1
Incidence of aplastic anemia: the relevance of diagnostic criteria. By the International Agranulocytosis and Aplastic Anemia Study.再生障碍性贫血的发病率:诊断标准的相关性。国际粒细胞缺乏症和再生障碍性贫血研究组
Blood. 1987 Dec;70(6):1718-21.
2
Relative incidence of agranulocytosis and aplastic anemia.粒细胞缺乏症和再生障碍性贫血的相对发病率。
Am J Hematol. 2006 Jan;81(1):65-7. doi: 10.1002/ajh.20489.
3
Agranulocytosis and aplastic anemia among Ramathibodi Hospital patients.
J Med Assoc Thai. 1992 Sep;75(9):514-6.
4
Incidence of aplastic anemia and agranulocytosis in Latin America--the LATIN study.拉丁美洲再生障碍性贫血和粒细胞缺乏症的发病率——拉丁研究
Sao Paulo Med J. 2005 May 2;123(3):101-4. doi: 10.1590/s1516-31802005000300002. Epub 2005 Jul 8.
5
Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. The International Agranulocytosis and Aplastic Anemia Study.粒细胞缺乏症和再生障碍性贫血的风险。关于它们与药物使用关系的首次报告,特别提及镇痛药。国际粒细胞缺乏症和再生障碍性贫血研究。
JAMA. 1986 Oct 3;256(13):1749-57.
6
Regional patterns in the incidence of aplastic anemia in Thailand. The Aplastic Anemia Study Group.泰国再生障碍性贫血发病率的区域模式。再生障碍性贫血研究小组。
Am J Hematol. 1999 Jul;61(3):164-8. doi: 10.1002/(sici)1096-8652(199907)61:3<164::aid-ajh2>3.0.co;2-r.
7
Transient pancytopenia. A report from the International Agranulocytosis and Aplastic Study.短暂性全血细胞减少症。来自国际粒细胞缺乏症和再生障碍性贫血研究的报告。
Blut. 1990 Oct;61(4):240-4. doi: 10.1007/BF01744138.
8
Incidence and cause of aplastic anemia, hemolytic anemia, agranulocytosis and thrombocytopenia.再生障碍性贫血、溶血性贫血、粒细胞缺乏症及血小板减少症的发病率及病因。
Acta Med Scand. 1981;210(6):475-9. doi: 10.1111/j.0954-6820.1981.tb09853.x.
9
Incidence and risk factors of aplastic anemia in Latin American countries: the LATIN case-control study.拉丁美洲国家再生障碍性贫血的发病率及危险因素:拉丁病例对照研究
Haematologica. 2009 Sep;94(9):1220-6. doi: 10.3324/haematol.2008.002642.
10
Risks of agranulocytosis and aplastic anemia in relation to the use of cardiovascular drugs: The International Agranulocytosis and Aplastic Anemia Study.与心血管药物使用相关的粒细胞缺乏症和再生障碍性贫血风险:国际粒细胞缺乏症和再生障碍性贫血研究
Clin Pharmacol Ther. 1991 Mar;49(3):330-41. doi: 10.1038/clpt.1991.37.

引用本文的文献

1
Somatic mutations and the efficacy of immunosuppressive therapy in severe/very severe aplastic anemia and transfusion-dependent nonsevere aplastic anemia.体细胞突变与免疫抑制疗法在重型/极重型再生障碍性贫血及输血依赖型非重型再生障碍性贫血中的疗效
Ann Hematol. 2025 Aug 7. doi: 10.1007/s00277-025-06393-z.
2
Targeting interleukin-2-inducible T cell kinase ameliorates immune-mediated aplastic anemia.靶向白细胞介素-2诱导的T细胞激酶可改善免疫介导的再生障碍性贫血。
Cancer Immunol Immunother. 2025 Apr 29;74(6):188. doi: 10.1007/s00262-025-04040-0.
3
The efficacy of immunosuppressive therapy with or without thrombopoietin receptor agonist in elderly patients with severe aplastic anemia.
在老年重型再生障碍性贫血患者中使用或不使用血小板生成素受体激动剂的免疫抑制疗法的疗效。
Ann Hematol. 2025 Mar;104(3):1515-1525. doi: 10.1007/s00277-025-06335-9. Epub 2025 Apr 7.
4
Clinical utility of hematological parameters in aplastic anemia.再生障碍性贫血血液学参数的临床应用价值
Sci Rep. 2025 Jan 23;15(1):2946. doi: 10.1038/s41598-025-86917-9.
5
Assessment of Malondialdehyde and Organochlorine Pesticides in Aplastic Anemia Severity Groups: Insights Into Oxidative Stress and Exposure.再生障碍性贫血严重程度分组中丙二醛和有机氯农药的评估:对氧化应激和暴露的见解
Cureus. 2024 May 5;16(5):e59698. doi: 10.7759/cureus.59698. eCollection 2024 May.
6
Aberrant myelomonocytic CD56 expression predicts response to cyclosporine therapy in pediatric patients with moderate aplastic anemia.异常的髓单核细胞CD56表达可预测中度再生障碍性贫血患儿对环孢素治疗的反应。
Front Pediatr. 2023 Dec 12;11:1272593. doi: 10.3389/fped.2023.1272593. eCollection 2023.
7
Plasma Levels of Organochlorine Pesticides and Tumor Necrosis Factor-Alpha: A Potential Risk Factor for Developing Acquired Aplastic Anemia in the North Indian Population.有机氯农药血浆水平与肿瘤坏死因子-α:印度北部人群发生获得性再生障碍性贫血的潜在危险因素
Cureus. 2023 Sep 28;15(9):e46122. doi: 10.7759/cureus.46122. eCollection 2023 Sep.
8
Development and validation of early death risk score model for emergency status prediction in very severe aplastic anemia.发展和验证用于预测极重型再生障碍性贫血急诊状态的早期死亡风险评分模型。
Front Immunol. 2023 Apr 20;14:1175048. doi: 10.3389/fimmu.2023.1175048. eCollection 2023.
9
Comparison of hematopoietic stem cell transplantation and immunosuppressive therapy as the first-line treatment option for patients with severe hepatitis-associated aplastic anemia.比较造血干细胞移植和免疫抑制治疗作为重型肝炎相关再生障碍性贫血患者的一线治疗选择。
Front Immunol. 2023 Mar 17;14:1146997. doi: 10.3389/fimmu.2023.1146997. eCollection 2023.
10
Herpes Simplex Virus-Associated Aplastic Anemia.单纯疱疹病毒相关性再生障碍性贫血
Cureus. 2023 Feb 22;15(2):e35320. doi: 10.7759/cureus.35320. eCollection 2023 Feb.